Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

Mosli, Mahmoud; Elyas, Moaiad

doi:10.4103/1319-3767.203362

Cited by 22 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another retrospective study, Mosli et al [ 22 ] compared the weight loss efficacy of adding liraglutide to an IGB in 108 patients, 64 of whom had an IGB inserted without liraglutide (ie, IGB-only), whereas 44 had an IGB inserted followed by liraglutide treatment (ie, IGB plus liraglutide). The patients’ mean age was 34.9 ± 9.8 years in the IGB-only group and 32.5 ± 8.4 years in the IGB with liraglutide group.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries

Imam,

Alim,

Binhussein

et al. 2023

Journal of the Endocrine Society

View full text Add to dashboard Cite

Background Different treatment modalities are available for obesity management, including lifestyle changes, pharmacotherapy, endoscopic interventions, and surgeries. Limited evidence is currently available on the weight loss effect of combining glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with endoscopic bariatric therapy (EBT) and bariatric surgeries (BS). Objectives In this systematic review we compared the weight loss effect and metabolic changes of combining GLP-1 RAs with EBT and BS. Methods Literature searches were performed in the Cochrane Database of Systematic Review, Cochrane Central Register of Controlled Trials, Embase, PubMed, Google Scholar, and PRISMA databases. Only randomized control trials and retrospective studies were included. Results A total of eleven studies were included. Nine studies compared BS with and without liraglutide and two compared EBT with and without liraglutide. Adding liraglutide to EBT or BS provided significant weight loss when compared with EBT or BS alone. When changes in weight were compared across the studies, EBT with liraglutide showed a weight loss effect comparable to the net weight loss (i.e., nadir weight loss after BS– regained weight) achieved following BS alone. Conclusion This review showcases a promising approach for managing obesity that combines GLP-1 RAs with EBT. This approach is expected to achieve shorter hospital stays, fewer side effects, and longer-term weight loss benefits than BS alone. However, additional prospective studies with higher-quality, more consistent outcome measures for weight loss and metabolic changes are needed to further evaluate the approach.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The results of Mosli et al's study [ 22 ] showed no advantages of administering liraglutide after the IGB insertion. Liraglutide was commenced 1 month after IGB insertion and stopped 1 month following IGB removal.…”

Section: Discussionmentioning

confidence: 99%

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries

Imam,

Alim,

Binhussein

et al. 2023

Journal of the Endocrine Society

View full text Add to dashboard Cite

show abstract

“…Studies examining the benefit of combination therapy—the IGB and anti-obesity pharmacotherapy—have attempted to address the concern about weight regain. Anti-obesity medication, such a liraglutide, used in combination with the IGB resulted in additional weight loss and more durable weight loss [ 25 •, 65 •]. As more effective anti-obesity medications, such as semaglutide, become more available, a combination approach with bariatric endoscopy procedures may represent the best non-surgical approach for weight loss for select patients.…”

Section: Utilization Of Bariatric Endoscopy Proceduresmentioning

confidence: 99%

Endobariatrics: a Still Underutilized Weight Loss Tool

Dave

Dawod

Simmons

2023

Curr Treat Options Gastro

View full text Add to dashboard Cite

Purpose of review Bariatric and metabolic endoscopic therapies provide an option for patients seeking clinically significant weight loss with fewer adverse events than conventional bariatric surgery. Our aims are to provide an overview of the current state of primary endoscopic treatment options for weight loss and to emphasize the importance of including these therapies when presenting weight loss options to qualified patients. Recent findings Bariatric endoscopy procedures are associated with a lower adverse event rate when compared to bariatric surgery and result in more weight loss than most existing pharmacotherapies approved by the Food and Drug Administration. Summary Sufficient evidence exists to implement bariatric endoscopic therapies—namely, the intragastric balloon and endoscopic sleeve gastroplasty—as safe and effective treatment options for weight loss when used in combination with lifestyle changes. However, bariatric endoscopy remains an underutilized option by weight management providers. Future studies are needed to identify patient and provider-level barriers to adopting endoscopic bariatric therapies as an option for the treatment of obesity.

show abstract

“…Additionally, decreased gastric emptying at 3 months after IGB placement correlated significantly with the percentage of total body weight loss (%TBWL) at 6 and 12 months [12]. Combining IGB with pharmacotherapy has produced mixed results [13,14]. However, recent research has demonstrated the positive impact of glucagon-like-peptide-1 (GLP-1) on initial weight loss and the prevention of weight regain after IGB removal [14,15 ▪ ].…”

Section: Intragastric Balloonsmentioning

confidence: 99%

Endoluminal bariatric and metabolic therapies: state-of-the-art

Bakheet

Badurdeen

Sartoretto

et al. 2023

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of review The aim of this review is to present the current state of the field, highlight recent developments, and describe the clinical outcomes of these endoluminal bariatric and metabolic procedures. Recent findings The landscape of endoluminal devices and techniques for treating obesity has expanded significantly, with FDA-approved therapies currently available to patients with a body mass index values as high as 50 kg/m2. Although notable advancements have been made in this area, there is a need for further emphasis to be placed on the metabolic improvements resulting from these therapies, in addition to the conventional focus on weight loss outcomes. Some of these procedures are now FDA approved for the treatment of metabolic disease as opposed to weight loss. To achieve the most favorable results, it is imperative that all endoluminal interventions are combined with a moderately intensive diet and lifestyle program lasting at least 12 months. Summary Endoluminal metabolic and bariatric therapy represents a bridge between lifestyle counseling, pharmaceutical interventions, and the most efficacious treatment for obesity, bariatric surgery. By virtue of its minimally invasive approach, this therapy may be an appealing option for patients who are ineligible for, or averse to, bariatric surgery and who have experienced suboptimal outcomes or unable to afford medical treatments. Furthermore, these interventions may be particularly beneficial in the early stages of obesity.

show abstract

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?

Cited by 22 publications

References 15 publications

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries

Endobariatrics: a Still Underutilized Weight Loss Tool

Endoluminal bariatric and metabolic therapies: state-of-the-art

Contact Info

Product

Resources

About